4-(2-bromophenyl)-6-methyl-2-piperazinyl-thieno[2,3-d]pyrimidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4-(2-bromophenyl)-6-methyl-2-piperazinyl-thieno[2,3-d]pyrimidine
• 英文别名: 4-(2-Bromophenyl)-6-methyl-2-piperazin-1-ylthieno[2,3-d]pyrimidine
• 化学式: C₁₇H₁₇BrN₄S
• 分子量: 389.319
• InChiKey: ATXVOBUCRXCIQY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  69.3
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Thieno(2,3-d)pyrimidine derivatives and salts thereof
  申请人：MITSUBISHI KASEI CORPORATION

  公开号：EP0150469A1

  公开（公告）日：1985-08-07

  This invention relates novel thieno[2,3-d]pyrimidine derivatives represented by the following general formula (I): or salts thereof; wherein R1 and R2 independently represent hydrogen, halogen or alkyl group having 1 to 6 carbon atoms; or R1 and R2 may concatenate to form a cycloalkylene group having 5 or 6 ring carbon atoms; R3 and R4 independently represent hydrogen or alkyl group having 1 to 6 carbon atoms; R5 represents a member selected from (1) hydrogen or alkyl having 1 to 6 carbon atoms, is an integer of from 1 to 3 and X represents halogen, or (3) in which R6 represents alkyl group having 1 to 6 carbon atoms; Ar represents substituted or unsubstituted phenyl, or 2- or 3-thienyl group; and n is 2 or 3. The derivatives of the invention can be used in the treatment of the various depression disease or the higher dysfunction of the brain.

  本发明涉及以下一般式(I)所表示的新型噻唑[2,3-d]嘧啶衍生物或其盐；其中，R1和R2独立地表示氢、卤素或具有1至6个碳原子的烷基；或者R1和R2可以连接形成具有5或6个环碳原子的环烷基；R3和R4独立地表示氢或具有1至6个碳原子的烷基；R5表示从(1)氢或具有1至6个碳原子的烷基，n为1至3的整数，X表示卤素，或者(3)式中，R6表示具有1至6个碳原子的烷基；Ar表示取代或未取代的苯基，或2-或3-噻吩基；n为2或3。本发明的衍生物可用于治疗各种抑郁症或大脑高级功能障碍。
• Soft tissue implants and drug combination compositions, and use thereof
  申请人：Hunter L. William

  公开号：US20070196421A1

  公开（公告）日：2007-08-23

  Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring drug combination in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.
• Anti-scarring drug combinations and use thereof
  申请人：Hunter L. William

  公开号：US20070208134A1

  公开（公告）日：2007-09-06

  The present invention provides devices or implants that comprise anti-scarring drug combinations, methods or making such devices or implants, and methods of inhibiting fibrosis between the devices or implants and tissue surrounding the devices or implants. The present invention also provides compositions that comprise anti-fibrotic drug combinations, and their uses in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.
• Implantable sensors, implantable pumps and anti-scarring drug combinations
  申请人：Hunter L. William

  公开号：US20070197957A1

  公开（公告）日：2007-08-23

  Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent or a composition that comprises an anti-scarring agent to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.
• Electrical devices and anti-scarring drug combinations
  申请人：Hunter L. William

  公开号：US20070198063A1

  公开（公告）日：2007-08-23

  Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring drug combination or a composition that comprises an anti-scarring drug combination to inhibit scarring that may otherwise occur when the devices are implanted within an animal.